> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Period Determined for Yescarta
- URL: https://www.fdaweb.com/review-period-determined-for-yescarta/
- Published: 2019-04-29T12:00:00.000Z
- Updated: 2026-09-15T01:23:07.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5143977

*Federal Register* notice: FDA has determined the regulatory review period for Cabaret Biotech’s Yescarta (axicabtagene ciloleucel), a CD 19- directed genetically modified autologous T cell immunotherapy indicated for treating adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The review period has been determined to be 3,243 days, including 3,041 days that occurred during the testing phase and 202 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-04-29/pdf/2019-08609.pdf?ref=fdaweb.com).